Mukul R Jain

This inventor holds 16 USPTO granted patents and 20 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignees: Cadila Healthcare Limited, Zydus Lifesciences Limited. Active years: 2008-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mukul R Jain. Retrieved from https://idiyas.com/inventor/mukul-r-jain

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 20)

% Patents Active = 50.0

CIPO Patents = 1

EPO Patents = 10 (Patent Applications = 16)

Average Co-Inventor Count = 3.9

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Ahmedabad, IN (2013 - 2014)
Gujarat, IN (2008 - 2024)

Company Filing History:

13 out of 131

Cadila Healthcare Limited

patents

3 out of 12

Zydus Lifesciences Limited

patents

Years Active: 2008-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12201609 - Saroglitazar for the treatment of hepatocellular carcinoma (2025-01-21),

2. 12178799 - Treatment for primary biliary cholangitis (2024-12-31),

3. 11872209 - Treatment for primary biliary cholangitis (2024-01-16),

4. 11433050 - Treatment for primary biliary cholangitis (2022-09-06),

5. 11325945 - Peptide based PCSK9 vaccine (2022-05-10),

6. 10315993 - Synergistic compositions (2019-06-11),

7. 9957230 - Synergistic compositions (2018-05-01),

8. 9656954 - Synergistic compositions (2017-05-23),

9. 8883963 - Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities (2014-11-11),

10. 8841413 - Antidiabetic compounds (2014-09-23),

11. 8835469 - Substituted benzamide derivatives as glucokinase (GK) activators (2014-09-16),

12. 8822414 - Heterocyclic compounds suitable for the treatment of dyslipidemia (2014-09-02),

13. 8772302 - GPR 119 agonists (2014-07-08),

14. 8742117 - Oxime derivatives (2014-06-03),

15. 8383581 - Short-chain peptides as parathyroid hormone (PTH) receptor agonist (2013-02-26),

Title: The Innovative Mind of Mukul R Jain

Introduction

Mukul R Jain, an accomplished inventor based in Gujarat, India, has made significant contributions to the field of pharmaceuticals with his innovative inventions. With a total of three patents to his name, Jain has established himself as a valuable asset in the medical research realm.

Latest Patents

Mukul R Jain's most notable patents include groundbreaking treatments aimed at combating serious diseases. One of his latest inventions is a pharmaceutical composition known as Saroglitazar, designed for the treatment of hepatocellular carcinoma. This invention focuses on the prevention, delay of progression, or treatment of this severe liver cancer, providing hope to many patients facing this diagnosis. Additionally, Jain has developed a therapeutic compound aimed at preventing and treating primary biliary cholangitis (PBC). This innovation includes a pharmaceutical composition comprising a compound of a specific formula, showcasing Jain's dedication to advancing medical treatments.

Career Highlights

Currently, Mukul R Jain is associated with Zydus Lifesciences Limited, a leading company in the pharmaceutical sector. His work there reflects his commitment to innovative healthcare solutions. Through his research and patent contributions, Jain continues to influence the field of pharmaceuticals positively.

Collaborations

Throughout his career, Mukul R Jain has collaborated with talented individuals, including his coworkers Suresh Giri and Deven V Parmar. These collaborations highlight the spirit of teamwork and innovation, essential in the pursuit of advanced medical solutions.

Conclusion

Mukul R Jain's work exemplifies the role of inventors in shaping healthcare through innovative techniques and treatments. With his focus on significant medical challenges, Jain continues to contribute to the betterment of human health, paving the way for future advancements. His patents not only solidify his position as a prominent inventor but also inspire others in the pharmaceutical field to pursue innovation.

Profile summary based on public USPTO records.